---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-26-000032"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2026-08-05T11:17:09+00:00"
generated_at: "2026-08-05T11:20:05.279172+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore Q2 revenue $34.2M, down 6.2% YoY; net loss $6.2M vs $1.1M loss last year

## Summary
- Revenue $34.2M, down 6.2% YoY; net loss $6.2M ($0.19 loss per share) vs $1.1M loss ($0.06) in prior year.
- Adjusted EBITDA $8.6M, down from $9.1M; free cash flow $0.9M for six months ended June 30, 2026.
- Reaffirmed 2026 guidance; targeting 12% revenue CAGR and >25% Adjusted EBITDA margin by end of 2029.
- Added 13 new programs in past 12 months, including 8 late-stage; 6 new programs signed in Q2 2026.
- Ended Q2 with $38.8M liquidity ($17.2M cash, $21.6M revolver availability).

## SEC filing metadata
- accession: 0001005286-26-000032
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2026-08-05T11:17:09+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/0001005286-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-26-000032
- JSON: https://secwatch.observer/filing/0001005286-26-000032.json
- Plain text: https://secwatch.observer/filing/0001005286-26-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.